International Edition
Latest News
Health

Alzheimer’s: New Blood Test Predicts Onset Years in Advance

Latest Blood Test Shows Promise in Predicting Alzheimer’s Disease Onset A new blood test measuring levels of a specific form of tau protein, known as p-tau217, is demonstrating remarkable accuracy in predicting the onset of Alzheimer’s disease, even…

Latest Blood Test Shows Promise in Predicting Alzheimer’s Disease Onset

A new blood test measuring levels of a specific form of tau protein, known as p-tau217, is demonstrating remarkable accuracy in predicting the onset of Alzheimer’s disease, even years before symptoms appear. This advancement offers a less invasive and more accessible alternative to existing diagnostic methods like PET scans and cerebrospinal fluid (CSF) analysis, potentially revolutionizing Alzheimer’s research and clinical care.

Understanding the Biomarker: p-tau217

Alzheimer’s disease is characterized by the buildup of amyloid plaques and tau tangles in the brain. The p-tau217 biomarker is a phosphorylated form of the tau protein and research indicates a strong correlation between its concentration in the blood and the presence of these pathological hallmarks in the brain [1]. Measuring p-tau217 in plasma allows for a relatively simple and cost-effective way to assess a person’s risk of developing Alzheimer’s.

Accuracy and Performance

Studies have shown the plasma p-tau217 test to be highly accurate. In a clinical validation set of 524 participants aged 60 and older with cognitive impairment, the test demonstrated a sensitivity of 90% and a specificity of 90% [2]. The area under the curve (AUC) for diagnostic accuracy was 0.941, indicating excellent performance. Importantly, the test’s results closely align with amyloid PET scan results, a current standard for diagnosing Alzheimer’s.

Comparison to Existing Methods

Currently, diagnosing Alzheimer’s often involves expensive and invasive procedures like PET imaging and CSF analysis. The p-tau217 blood test offers a compelling alternative. Recent research suggests that plasma %p-tau217 (the ratio of phosphorylated-tau217 to non-phosphorylated tau) performs as well as, or even better than, FDA-approved CSF tests in detecting Alzheimer’s pathology [3]. Head-to-head comparisons also indicate that increases in plasma p-tau217 are superior at detecting Alzheimer’s pathology and predicting future development of Alzheimer’s dementia [4].

Clinical Implications and Future Directions

The development of an accurate blood test for Alzheimer’s has significant implications for several areas:

  • Early Detection: Identifying individuals at risk before symptoms develop allows for earlier intervention and potential enrollment in clinical trials.
  • Improved Diagnosis: The test can aid in more accurate and efficient diagnosis, reducing the need for more invasive procedures.
  • Drug Development: Facilitates the identification of suitable candidates for emerging disease-modifying therapies.

While the p-tau217 test is a significant step forward, it’s crucial to remember that it is not a standalone diagnostic tool. It should be used as part of a comprehensive diagnostic workup, alongside clinical evaluation and other relevant tests [2]. Further research is ongoing to refine the test and explore its potential for monitoring disease progression and treatment response.

Frequently Asked Questions

Q: Is this test widely available?
A: While the test is becoming more available, it is not yet universally accessible. Availability varies by laboratory and healthcare provider.

Q: Can this test tell me if I *will* get Alzheimer’s?
A: The test can indicate an increased risk of developing Alzheimer’s, but it cannot definitively predict whether someone will develop the disease. Many factors contribute to Alzheimer’s development.

Q: What does an “indeterminate” result mean?
A: An indeterminate result means the test did not provide a clear positive or negative finding. Further investigation may be needed.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”